Oxygen therapy use in older adults with chronic obstructive pulmonary disease

Shawn P E Nishi, Wei Zhang, Yong-Fang Kuo, Gulshan Sharma, Shawn P E Nishi, Wei Zhang, Yong-Fang Kuo, Gulshan Sharma

Abstract

Rationale: Oxygen therapy improves survival and function in severely hypoxemic chronic obstructive pulmonary disease (COPD) patients based on two landmark studies conducted over 40 years ago. We hypothesize that oxygen users in the current era may be very different. We examined trends and subject characteristics associated with oxygen therapy use from 2001-2010 in the United States.

Methods: We examined Medicare beneficiaries with COPD who received oxygen from 2001 to 2010. COPD subjects were identified by: 1) ≥2 outpatient visits >30 days apart within one year with an encounter diagnosis of COPD; or 2) an acute care hospitalization with COPD as the primary or secondary discharge diagnosis. Oxygen therapy and sustained oxygen therapy were defined as ≥1 and ≥11 claims for oxygen, respectively, in the durable medical equipment file in a calendar year. Primary outcome measures were factors associated with oxygen therapy and sustained oxygen therapy over the study period.

Results: Oxygen therapy increased from 33.7% in 2001 to 40.5% in 2010 (p-value of trend <0.001). Sustained oxygen therapy use increased from 19.5% in 2001, peaked in 2008 to 26.9% and declined to 18.5% in 2010. The majority of subjects receiving oxygen therapy and sustained oxygen therapy were female. Besides gender, factors associated with any oxygen use or sustained oxygen therapy were non-Hispanic white race, low socioeconomic status and ≥2 comorbidities.

Conclusions: Any oxygen use among fee-for service Medicare beneficiaries with COPD is high. Current users of oxygen are older females with multiple comorbidities. Decline in sustained oxygen therapy use after 2008 may be related to reimbursement policy change.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Fig 1. Annual percent of oxygen therapy…
Fig 1. Annual percent of oxygen therapy and Sustained oxygen therapy use from 2001–2010.
Fig 2. Any oxygen use by age…
Fig 2. Any oxygen use by age groups, (a), and sustained oxygen therapy use by age group, (b).
Fig 3. Any oxygen use by gender,…
Fig 3. Any oxygen use by gender, (a), and sustained oxygen therapy use by gender, (b).
Fig 4. Any oxygen use by race,…
Fig 4. Any oxygen use by race, (a), and sustained oxygen therapy use by race, (b).
Fig 5. Any oxygen use by comorbidities,…
Fig 5. Any oxygen use by comorbidities, (a), and sustained oxygen therapy use by comorbidities, (b).

References

    1. Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med, 1980. 93(3): p. 391–8.
    1. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet, 1981. 1(8222): p. 681–6.
    1. Zieliński J, Tobiasz M, Hawryłkiewicz I, Sliwiński P, Pałasiewicz G. Effects of long-term oxygen therapy on pulmonary hemodynamics in COPD patients: a 6-year prospective study. Chest, 1998. 113(1): p. 65–70.
    1. Borak J, Sliwiński P, Tobiasz M, Górecka D, Zieliński J. Psychological status of COPD patients before and after one year of long-term oxygen therapy. Monaldi Arch Chest Dis, 1996. 51(1): p. 7–11.
    1. New problems in supply, reimbursement and certification of medical necessity for long-term oxygen therapy., in American review of respiratory disease 1990. p. 721–724.
    1. MEDICARE HOME OXYGEN: Refining Payment Methodology Has Potential to Lower Program and Beneficiary Spending. 2011.
    1. Medicare Coverage Database, MCD Chapter 240.2. Available: . Accessed: 2013 Apr 11.
    1. Doherty DE, Petty TL, Bailey W, Carlin B, Cassaburi R, Christopher K, et al. Recommendations of the 6th long-term oxygen therapy consensus conference. Respir Care, 2006. 51(5): p. 519–25.
    1. Global Strategy for Diagnosis, Management, and Prevention of COPD. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2014 January 2014. Available: . Accessed: 2014 May 15.
    1. Mannino DM, Braman S. The epidemiology and economics of chronic obstructive pulmonary disease. Proc Am Thorac Soc, 2007. 4(7): p. 502–6.
    1. Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care, 1998. 36(1): p. 8–27.
    1. Medicare data file descriptions. Available: . Accessed: 2013 Jan 24.
    1. Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC. Chronic obstructive pulmonary disease surveillance—United States, 1971–2000. MMWR Surveill Summ, 2002. 51(6): p. 1–16.
    1. Suh DC, Lau H, Pokras SM, Choi IS, Valiyeva E. Sex differences in ambulatory visits for chronic obstructive pulmonary disease, based on the National Ambulatory Medical Care Survey and the National Hospital Ambulatory Medical Care Survey from 1995 to 2004. Respir Care, 2008. 53(11): p. 1461–9.
    1. Akinmabi LJ, Liu X. Chronic Obstructive Pulmonary Disease Among Adults Aged 18 and Over in the United States, 1998–2009, Brief N.D., Editor. June 2011, Centers for Disease Control and Prevention; 10.7556/jaoa.2013.045
    1. Ringbaek TJ, Lange P. Trends in long-term oxygen therapy for COPD in Denmark from 2001 to 2010. Respir Med, 2013.
    1. Behavioural Risk Factor Surveillance—United States, 2011, C.f.D.C.a.P.U.S.D.o.H.a.H. Services., Editor., American Lung Association Research and Health Education.
    1. Xu X, Li B, Wang L. Gender difference in smoking effects on adult pulmonary function. Eur Respir J, 1994. 7(3): p. 477–83.
    1. Prescott E, Bjerg AM, Andersen PK, Lange P, Vestbo J. Gender difference in smoking effects on lung function and risk of hospitalization for COPD: results from a Danish longitudinal population study. Eur Respir J, 1997. 10(4): p. 822–7.
    1. Langhammer A, Johnsen R, Gulsvik A, Holmen TL, Bjermer L. Sex differences in lung vulnerability to tobacco smoking. Eur Respir J, 2003. 21(6): p. 1017–23.
    1. Chapman KR. Chronic obstructive pulmonary disease: are women more susceptible than men? Clin Chest Med, 2004. 25(2): p. 331–41.
    1. Dransfield MT, Davis JJ, Gerald LB, Bailey WC. Racial and gender differences in susceptibility to tobacco smoke among patients with chronic obstructive pulmonary disease. Respir Med, 2006. 100(6): p. 1110–6.
    1. Akpunonu B, Mutgi A, Federman D, Donabedian H, Wasielewski N, Lachant M, et al. Inappropriate use of oxygen: loss of a valuable healthcare resource. Am J Med Sci, 1994. 308(4): p. 244–6.
    1. Morrison D, Skwarski K, MacNee W. Review of the prescription of domiciliary long term oxygen therapy in Scotland. Thorax, 1995. 50(10): p. 1103–5.
    1. Oba Y, Salzman GA, Willsie SK. Reevaluation of continuous oxygen therapy after initial prescription in patients with chronic obstructive pulmonary disease. Respir Care, 2000. 45(4): p. 401–6.
    1. Ringbaek TJ, Lange P. The impact of the Danish Oxygen Register on adherence to guidelines for long-term oxygen therapy in COPD patients. Respir Med, 2006. 100(2): p. 218–25.
    1. Ström K, Boe J, Boman G, Midgren B, Rosenhall L. Long-term domiciliary oxygen therapy. Experiences acquired from the Swedish Oxygen Register. Monaldi Arch Chest Dis, 1993. 48(5): p. 473–8.
    1. Guyatt GH, McKim DA, Austin P, Bryan R, Norgren J, Weaver B, et al. Appropriateness of domiciliary oxygen delivery. Chest, 2000. 118(5): p. 1303–8.
    1. Chaney JC, Jones K, Grathwohl K, Olivier KN. Implementation of an oxygen therapy clinic to manage users of long-term oxygen therapy. Chest, 2002. 122(5): p. 1661–7.
    1. Wisely C. Five Things Physicians and Patients Should Question. 2013 Available: . Accessed: 2014 May 15.
    1. Defi cit Reduction Act, in 42 USC 1395m(a)(5) §5101 (b), Pub L No. 109–171 amended.
    1. Details for: EXPANSION OF COMPETITIVE BIDDING PROGRAM WILL INCREASE COMPETITION, MAINTAIN QUALITY, AND SAVE MEDICARE BILLIONS. Jan 2013.
    1. Johnston K, Grimmer-Somers K. Pulmonary rehabilitation: overwhelming evidence but lost in translation? Physiother Can, 2010. 62(4): p. 368–73. 10.3138/physio.62.4.368
    1. Keating A, Lee A, Holland AE. What prevents people with chronic obstructive pulmonary disease from attending pulmonary rehabilitation? A systematic review. Chron Respir Dis, 2011. 8(2): p. 89–99. 10.1177/1479972310393756
    1. Hayton C, Clark A, Olive S, Browne P, Galey P, Knights E. Barriers to pulmonary rehabilitation: characteristics that predict patient attendance and adherence. Respir Med, 2013. 107(3): p. 401–7. 10.1016/j.rmed.2012.11.016
    1. O'Donohue WJ Jr, Plummer AL. Magnitude of usage and cost of home oxygen therapy in the United States. Chest, 1995. 107(2): p. 301–2.
    1. Han MK, Kim MG, Mardon R, Renner P, Sullivan S, Diette GB. Spirometry utilization for COPD: how do we measure up? Chest, 2007. 132(2): p. 403–9.
    1. Mularski RA, Asch SM, Shrank WH, Kerr EA, Setodji CM, Adams JL. The quality of obstructive lung disease care for adults in the United States as measured by adherence to recommended processes. Chest, 2006. 130(6): p. 1844–50.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever